Neutrophil membrane-coated therapeutic liposomes for targeted treatment in acute lung injury

Huang, Zhiwei; Wang, Hengcai; Long, Juan; Lu, Zhongqiu; Chun, Changbum; Li, Xinze

doi:10.1016/j.ijpharm.2022.121971

Cited by 10 publications

(4 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, aFGF@NMLs improved the therapeutic effect and enhanced lung function recovery. 69 This experimental result provides great potential for the development of neutrophil membrane-coated liposome-loaded cancer drugs for the treatment of gliomas in the near future.…”

Section: Liposomes As Drug Carriersmentioning

confidence: 79%

“…In another instance, in 2022, Huang, Zhiwei et al prepared the aFGF@NML biomimetic nanoplatform by loading a neutrophil membrane-coated liposome with aFGF for treating sepsis-induced acute lung injury (ALI). 69 In vitro studies revealed that aFGF@NMLs improved the cellular antioxidant capacity and significantly inhibited inflammatory responses. The in vivo ALI model results demonstrated that aFGF@NMLs selectively accumulated in injured lungs after intravenous administration.…”

Section: Liposomes As Drug Carriersmentioning

confidence: 99%

“…Neutrophilcoated magnetic nanoprobes can increase the imaging resolution, and also be used for the diagnosis of various types of diseases. 68,69 The encapsulation of drug molecules in a liposome that is coated with a neutrophil membrane can improve the drug penetration in the brain tumor site, drug loading, biocompatibility, and pharmacokinetics. For example, in 2017, Xue, Jingwei et al reported the design and development of neutrophil-mediated delivery of liposome-paclitaxel (PTX) to penetrate the BBB.…”

Section: Biomimetic Liposomes For Application In Brain Tumorsmentioning

confidence: 99%

See 2 more Smart Citations

A state-of-the-art liposome technology for glioblastoma treatment

Hasan,

Roy,

Ehexige

et al. 2023

Nanoscale

View full text Add to dashboard Cite

show abstract

Section: Liposomes As Drug Carriersmentioning

confidence: 79%

Section: Liposomes As Drug Carriersmentioning

confidence: 99%

Section: Biomimetic Liposomes For Application In Brain Tumorsmentioning

confidence: 99%

See 1 more Smart Citation

A state-of-the-art liposome technology for glioblastoma treatment

Hasan,

Roy,

Ehexige

et al. 2023

Nanoscale

View full text Add to dashboard Cite

show abstract

“…[7,8] Utilizing the inherent tropism of neutrophils toward inflammatory sites, our prior research demonstrated that neutrophil membrane-camouflaged vehicles can precisely deliver therapeutic agents to inflammatory sites for the relief of ulcerative colitis and sepsis-induced ALI. [9,10] Additionally, we have developed erythrocyte membrane-encapsulated poly(lacticco-glycolic acid) (PLGA) nanoparticles to load basic fibroblast growth factor (bFGF), thus extending the residence time of bFGF in the bloodstream for treating sepsis-associated cardiac injury. [11] As functional cell membrane-derived nanoparticles gain a wide range of applications, cytomembrane employed in biomimetic vehicles is going through a shift from natural to modified.…”

Section: Introductionmentioning

confidence: 99%

Efferocytosis‐Inspired Biomimetic Nanoplatform for Targeted Acute Lung Injury Therapy

Huang,

Li,

et al. 2024

Adv Healthcare Materials

Self Cite

View full text Add to dashboard Cite

Acute lung injury (ALI) is a serious inflammatory disease that causes impairment of pulmonary function. Phenotypic modulation of macrophage in the lung using fibroblast growth factor 21 (FGF21) may be a potential strategy to alleviate lung inflammation. Consequently, achieving specific delivery of FGF21 to the inflamed lung and subsequent efficient FGF21 internalization by macrophages within the lung becomes critical for effective ALI treatment. Here, we report an apoptotic cell membrane‐coated zirconium‐based metal‐organic framework UiO‐66 for precise pulmonary delivery of FGF21 (ACM@U‐FGF21) whose design is inspired by the process of efferocytosis. ACM@U‐FGF21 with apoptotic signals is recognized and internalized by phagocytes in the blood and macrophages in the lung, and then the intracellular ACM@U‐FGF21 can inhibit the excessive secretion of pro‐inflammatory cytokines by these cells to relieve the inflammation. Utilizing the homologous targeting properties inherited from the source cells and the spontaneous recruitment of immune cells to inflammatory sites, ACM@U‐FGF21 can accumulate preferentially in the lung after injection. The results prove that ACM@U‐FGF21 effectively reduce inflammatory damage to the lung by modulating lung macrophage polarization and suppressing the excessive secretion of pro‐inflammatory cytokines by activated immune cells. This study demonstrates the usefulness of efferocytosis‐inspired ACM@U‐FGF21 in the treatment of ALI.This article is protected by copyright. All rights reserved

show abstract

BV2 Membrane‐Coated PEGylated‐Liposomes Delivered hFGF21 to Cortical and Hippocampal Microglia for Alzheimer's Disease Therapy

Wang,

Yang,

et al. 2024

Adv Healthcare Materials

View full text Add to dashboard Cite

Microglia‐mediated inflammation is involved in the pathogenesis of Alzheimer's disease (AD), whereas hFGF21 has demonstrated the ability to regulate microglia activation in Parkinson's disease, indicating a potential therapeutic role in AD. However, challenges such as aggregation, rapid inactivation, and the blood‐brain barrier hinder its effectiveness in treating AD. This study develops targeted delivery of hFGF21 to activated microglia using BV2 membrane‐coated PEGylated liposomes (hFGF21@BCM‐LIP), preserving the bioactivity of hFGF21. In vitro, hFGF21@BCM‐LIP specifically targets Aβ1‐42‐induced BV2 cells, with uptake hindered by anti‐VCAM‐1 antibody, indicating the importance of VCAM‐1 and integrin α4/β1 interaction in targeted delivery to BV2 cells. In vivo, following subcutaneous injection near the lymph nodes of the neck, hFGF21@BCM‐LIP diffuses into lymph nodes and distributes along the meningeal lymphatic vasculature and brain parenchyma in Aβ1‐42‐induced mice. Furthermore, the administration of hFGF21@BCM‐LIP to activated microglia improves cognitive deficits caused by Aβ1‐42 and reduces levels of tau, p‐Tau, and BACE1. It also decreases IL‐6 and TNF‐α release while increasing IL‐10 release both in vivo and in vitro. These results indicate that hFGF21@BCM‐LIP could be a promising treatment for AD, by effectively crossing the blood‐brain barrier and targeting delivery to brain microglia via the neck‐meningeal lymphatic vasculature‐brain parenchyma pathways.This article is protected by copyright. All rights reserved

show abstract

Neutrophil membrane-coated therapeutic liposomes for targeted treatment in acute lung injury

Cited by 10 publications

References 55 publications

A state-of-the-art liposome technology for glioblastoma treatment

A state-of-the-art liposome technology for glioblastoma treatment

Efferocytosis‐Inspired Biomimetic Nanoplatform for Targeted Acute Lung Injury Therapy

BV2 Membrane‐Coated PEGylated‐Liposomes Delivered hFGF21 to Cortical and Hippocampal Microglia for Alzheimer's Disease Therapy

Contact Info

Product

Resources

About